Literature DB >> 20491622

Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Ivan Stamenkovic1, Qin Yu.   

Abstract

Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of schwannomas, meningiomas, and ependymomas. Mutations of NF2 gene were also found in thyroid cancer, mesothelioma, and melanoma, suggesting that it functions as a tumor suppressor in a wide spectrum of cells. The product of NF2 gene is merlin (moesin-ezrin-radixin-like protein), a member of the Band 4.1 superfamily proteins. Merlin shares significant sequence homology with the ERM (Ezrin-Radixin-Moesin) family proteins and serves as a linker between transmembrane proteins and the actin-cytoskeleton. Merlin is a multifunctional protein and involved in integrating and regulating the extracellular cues and intracellular signaling pathways that control cell fate, shape, proliferation, survival, and motility. Recent studies showed that merlin regulates the cell-cell and cell-matrix adhesions and functions of the cell surface adhesion/extracellular matrix receptors including CD44 and that merlin and CD44 antagonize each other's function and work upstream of the mammalian Hippo signaling pathway. Furthermore, merlin plays important roles in stabilizing the contact inhibition of proliferation and in regulating activities of several receptor tyrosine kinases. Accumulating data also suggested an emerging role of merlin as a negative regulator of growth and progression of several non-NF2 associated cancer types. Together, these recent advances have improved our basic understanding about merlin function, its regulation, and the major signaling pathways regulated by merlin and provided the foundation for future translation of these findings into the clinic for patients bearing the cancers in which merlin function and/or its downstream signaling pathways are impaired or altered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491622      PMCID: PMC2946555          DOI: 10.2174/138920310791824011

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  196 in total

Review 1.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 2.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

3.  Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase.

Authors:  Hongchuan Jin; Tobias Sperka; Peter Herrlich; Helen Morrison
Journal:  Nature       Date:  2006-08-03       Impact factor: 49.962

4.  The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size.

Authors:  Maria Willecke; Fisun Hamaratoglu; Madhuri Kango-Singh; Ryan Udan; Chiao-Lin Chen; Chunyao Tao; Xinwei Zhang; Georg Halder
Journal:  Curr Biol       Date:  2006-09-21       Impact factor: 10.834

5.  The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling.

Authors:  Sushmita Maitra; Rima M Kulikauskas; Heather Gavilan; Richard G Fehon
Journal:  Curr Biol       Date:  2006-04-04       Impact factor: 10.834

6.  Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling.

Authors:  Daniel R Scoles; Vu D Nguyen; Yun Qin; Chun-Xiao Sun; Helen Morrison; David H Gutmann; Stefan-M Pulst
Journal:  Hum Mol Genet       Date:  2002-12-01       Impact factor: 6.150

7.  Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

Authors:  Miguel A López-Lago; Tomoyo Okada; Miguel M Murillo; Nick Socci; Filippo G Giancotti
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

8.  Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity.

Authors:  John Peter McPherson; Laura Tamblyn; Andrew Elia; Eva Migon; Amro Shehabeldin; Elzbieta Matysiak-Zablocki; Bénédicte Lemmers; Leonardo Salmena; Anne Hakem; Jason Fish; Farah Kassam; Jeremy Squire; Benoit G Bruneau; M Prakash Hande; Razqallah Hakem
Journal:  EMBO J       Date:  2004-09-02       Impact factor: 11.598

9.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

10.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08
View more
  62 in total

1.  A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.

Authors:  Alejandra M Petrilli; Marisa A Fuse; Mathew S Donnan; Marga Bott; Nicklaus A Sparrow; Daniel Tondera; Julia Huffziger; Corina Frenzel; C Siobhan Malany; Christophe J Echeverri; Layton Smith; Cristina Fernández-Valle
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 3.  Osteopontin: At the cross-roads of myocyte survival and myocardial function.

Authors:  Mahipal Singh; Suman Dalal; Krishna Singh
Journal:  Life Sci       Date:  2014-09-28       Impact factor: 5.037

4.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

5.  Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.

Authors:  Assunta De Rienzo; William G Richards; Beow Y Yeap; Melissa H Coleman; Peter E Sugarbaker; Lucian R Chirieac; Yaoyu E Wang; John Quackenbush; Roderick V Jensen; Raphael Bueno
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

6.  Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2.

Authors:  Prasanth S Ariyannur; Narendranath Vikkath; Ashok B Pillai
Journal:  Cancer Microenviron       Date:  2018-08-25

Review 7.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

8.  Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Authors:  Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

9.  CD44 regulation of endothelial cell proliferation and apoptosis via modulation of CD31 and VE-cadherin expression.

Authors:  Masayuki Tsuneki; Joseph A Madri
Journal:  J Biol Chem       Date:  2014-01-14       Impact factor: 5.157

10.  FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Authors:  Silvia Licciulli; Jasna Maksimoska; Chun Zhou; Scott Troutman; Smitha Kota; Qin Liu; Sergio Duron; David Campbell; Jonathan Chernoff; Jeffrey Field; Ronen Marmorstein; Joseph L Kissil
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.